Tumor uptake on 18FDOPA PET/CT is a strong prognostic factor in patients with metastatic small intestine neuroendocrine tumors (siNETs) – A GTE study

#3639

Introduction: 18FDOPA PET/CT has high diagnostic performances for siNETs. Its prognostic role is unknown.

Aim(s): To explore the prognostic impact of tumor uptake on 18FDOPA PET/CT in patients with metastatic siNETs.

Materials and methods: We included all consecutive patients with metastatic siNET who underwent at least one 18FDOPA PET/CT in five GTE expert centres from 2010 and 2020 (n=252), into a test cohort (n=166) and a full-external validation cohort (n=86). We measured the maximal standardized uptake value (SUVpeak) of the tumor (T) and non-tumor liver (H) on each 18FDOPA PET/CT examination. We measured overall survival (OS) from the date of PET/CT and assessed prognostic factors using Kaplan Meier and multivariable Cox proportional hazard analyses in the test cohort, with replication in the validation cohort.

Conference:

Presenting Author: de Mestier L

Authors: de Rycke O, Imperiale A, Perrier M, Bando-Delaunay A, Mennetrey C,

Keywords: FDOPA PET/CT, prognosis, small intestine NETs,